Knowing When to Pivot Without Starting Over: Interview with ABK Biomedical CEO Michael Mangano

In this episode, we sat down with Michael Mangano, President and CEO of ABK Biomedical.  ABK’s Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer. Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million. In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.